Health ❯ Obesity ❯ Weight Loss

Medications

Mounjaro GLP-1 Receptor Agonists Semaglutide GLP-1 Drugs Ozempic GLP-1 Agonists Zepbound Tirzepatide Wegovy Long-term Effects NHS GLP-1 Therapies GLP-1 Injections Ozempic and Wegovy Long-term Use Side Effects GLP-1s Copycat Drugs Orforglipron Eli Lilly GLP-1 Semaglutide and Tirzepatide Mounjaro and Wegovy Semaglutides Wegovy and Ozempic Medicare and Medicaid Coverage Novo Nordisk NHS Services GLP-1RA Benefits Diabetes Treatment Public Opinion Clinical Trials

EMA Panel Backs Higher 7.2 mg Wegovy Dose for Obesity

A European Commission ruling will determine EU availability next.

WHO Endorses GLP‑1s for Obesity as Australia Adds Class‑Wide Mental Health Warning

GLP-1 Drugs Linked to Lower Five-Year Death Risk in Colon Cancer, UCSD Study Finds

White House Finalizes GLP-1 Price Deal With Lilly and Novo, Setting $50 Medicare Copays

Pilot Study Ties GLP-1 Drugs to Slower Alcohol Absorption and Milder Intoxication

Meta-Analysis Finds Predictable Weight Rebound After Stopping Anti-Obesity Drugs

GLP-1 Weight-Loss Drugs Linked to Testosterone Normalization in Men

GLP-1 Drugs Linked to Lower Cancer Risk and Mortality in New Study